Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Maddalena Grieco, Alessandra Giorgi, Maria Cristina Gentile, et al.
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 170

Showing 1-25 of 170 citing articles:

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 962
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Marlene Chakhtoura, Rachelle Haber, Malak Ghezzawi, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101882-101882
Open Access | Times Cited: 249
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Xin Zhao, Minghe Wang, Zhitong Wen, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 247
The Glymphatic System: A Novel Component of Fundamental Neurobiology
Lauren M. Hablitz, Maiken Nedergaard
Journal of Neuroscience (2021) Vol. 41, Iss. 37, pp. 7698-7711
Open Access | Times Cited: 224
Lipid metabolism and lipid signals in aging and longevity
Ayse Sena Mutlu, Jonathon Duffy, Meng C. Wang
Developmental Cell (2021) Vol. 56, Iss. 10, pp. 1394-1407
Open Access | Times Cited: 170
Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists
Xin Zhang, Matthew J. Belousoff, Peishen Zhao, et al.
Molecular Cell (2020) Vol. 80, Iss. 3, pp. 485-500.e7
Open Access | Times Cited: 168
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
Caroline Holm Nørgaard, Sarah Friedrich, Charlotte T. Hansen, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 107
Therapeutic Potential of Natural Products in Treating Neurodegenerative Disorders and Their Future Prospects and Challenges
Md. Habibur Rahman, Johny Bajgai, Ailyn Fadriquela, et al.
Molecules (2021) Vol. 26, Iss. 17, pp. 5327-5327
Open Access | Times Cited: 103
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Syed Faizan Mehdi, Suma Pusapati, Muhammad Saad Anwar, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 93
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Dhruv Gupta, et al.
Ageing Research Reviews (2023) Vol. 89, pp. 101979-101979
Open Access | Times Cited: 78
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL , a randomized trial, design and baseline characteristics
Darren K. McGuire, Rodica Pop‐Busui, John Deanfield, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 7, pp. 1932-1941
Open Access | Times Cited: 72
GLP-1a: Going beyond Traditional Use
Lucas Fornari Laurindo, Sandra Maria Barbalho, Élen Landgraf Guiguer, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 739-739
Open Access | Times Cited: 70
Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
Manoj K. Mahapatra, Muthukumar Karuppasamy, Biswa Mohan Sahoo
Pharmaceutical Research (2022) Vol. 39, Iss. 6, pp. 1233-1248
Open Access | Times Cited: 69
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Saleh Hadi Alharbi
Therapeutic Advances in Endocrinology and Metabolism (2024) Vol. 15
Open Access | Times Cited: 61
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease
Jeffrey L. Cummings, Alireza Atri, Howard Feldman, et al.
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 3
Associations Between Diabetes Mellitus and Neurodegenerative Diseases
Leszek Szablewski
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 542-542
Open Access | Times Cited: 2
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
Hertzel C. Gerstein, Robert G. Hart, Helen M. Colhoun, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 8, Iss. 2, pp. 106-114
Closed Access | Times Cited: 102
The Relevance of Insulin Action in the Dopaminergic System
Francesca Fiory, Giuseppe Perruolo, Ilaria Cimmino, et al.
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 93
Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis
Jianbo Zhou, Xingyao Tang, Min Han, et al.
Metabolism (2020) Vol. 109, pp. 154265-154265
Open Access | Times Cited: 80
Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease—Current Knowledge, Mechanisms and Perspectives
Kristoffer Kjærgaard, Anne Catrine Daugaard Mikkelsen, Charlotte Wernberg, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 4, pp. 673-673
Open Access | Times Cited: 77
Immunotherapies for Neurodegenerative Diseases
Ibrahim Mortada, Raymond Farah, Sanaa Nabha, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 76
Bile Acids as Key Modulators of the Brain-Gut-Microbiota Axis in Alzheimer’s Disease
Agata Mulak
Journal of Alzheimer s Disease (2021) Vol. 84, Iss. 2, pp. 461-477
Open Access | Times Cited: 68
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Paul Edison
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 217-229
Open Access | Times Cited: 63
Diabetes, antidiabetic medications and risk of depression – A population-based cohort and nested case-control study
Ida Kim Wium‐Andersen, Merete Osler, Martin Balslev Jørgensen, et al.
Psychoneuroendocrinology (2022) Vol. 140, pp. 105715-105715
Open Access | Times Cited: 49
Inside the diabetic brain: Insulin resistance and molecular mechanism associated with cognitive impairment and its possible therapeutic strategies
Bhaskar Jyoti Dutta, Shamsher Singh, Sanket Seksaria, et al.
Pharmacological Research (2022) Vol. 182, pp. 106358-106358
Closed Access | Times Cited: 39
Page 1 - Next Page

Scroll to top